IMTS Expert Perspective
Do Not Miss These Key Points While Drafting a Clinical Evaluation Report
A defensible CER must do more than summarize literature. It must connect the device, clinical benefits, evidence requirements, state of the art, benchmarks, benefit risk, and postmarket obligations into one traceable evaluation.
The central question: does the clinical evidence verify the safety, performance, and clinical benefits of the device when it is used as intended, and does it support an acceptable benefit risk profile?
A CER should answer that question for the complete device scope. It should not read as a collection of disconnected summaries. The document must make the evaluation logic visible from the device description and intended purpose through the evidence appraisal, analysis, benefit risk determination, and plan for addressing remaining gaps.
Before drafting, establish the authoritative versions of the intended purpose, indications, contraindications, claims, device variants, risk management file, labeling, preclinical and clinical evidence, PMS information, and PMCF commitments. Misalignment among those sources can undermine an otherwise well written report.
Seven connected review questions
Use each question to test the strength of the evaluation.
- 01
Is the device clearly defined?
Describe the intended purpose, indications, patient population, medical conditions, users, use environment, variants, accessories, key components, software, materials or formulation, principle of operation, mode of action, and novel features as applicable.
- 02
Are the clinical benefits explicit and supportable?
Define each claimed clinical benefit and the conditions of use, then connect it to outcomes and clinical evidence that can substantiate the claim.
- 03
Is the required level of evidence justified?
Explain why the quantity and quality of evidence are sufficient for the device, risk class, novelty, intended purpose, target population, claims, and remaining uncertainties.
- 04
Does the state of the art establish the right context?
Describe the disease, accepted practice, available alternatives, relevant devices, clinical outcomes, benefits, risks, and unmet needs for the same indications and populations.
- 05
Are safety and performance benchmarks defensible?
Use aggregate evidence such as systematic reviews, guidelines, registries, and appropriate studies. If one device or dataset is used as a benchmark, explain why it is representative.
- 06
Is benefit risk evaluated against current practice?
Compare the subject device evidence with justified clinical benchmarks and determine whether benefits outweigh residual risks for every intended purpose and indication.
- 07
Do the conclusions cover the complete device scope?
Address all indications, populations, variants, combinations, accessories, expected lifetime, identified risks, residual risks, evidence gaps, and postmarket commitments.
Cross document consistency
The CER should reflect the same controlled evidence story as the technical documentation.
| Shared element | Documents to reconcile |
|---|---|
| Intended purpose and claims | CEP, CER, IFU, labeling, risk management, SSCP, and regulatory submission documents. |
| Risks and undesirable side effects | CER, risk management, PMS, PMCF, PSUR, complaints, vigilance, CAPA, IFU, and SSCP. |
| Clinical benefits and outcomes | CEP, CER, clinical investigation documents, PMCF, labeling, claims, and SSCP. |
| Evidence gaps and commitments | CER, PMS plan, PMCF plan, postmarket studies, PSUR, and planned update cycles. |
A change in one controlled source should trigger an impact assessment across the connected system. For example, a new postmarket signal may alter the CER conclusion, risk controls, labeling, PMCF priorities, PSUR assessment, and SSCP. Consistency is therefore a lifecycle control, not a final proofreading task.
The final review test
Could an independent reviewer reproduce the reasoning?
Before approval, confirm that each important conclusion can be traced backward to appraised evidence and forward to an appropriate action. Search methods, selection decisions, appraisal criteria, data tables, benchmark derivation, acceptance criteria, and evidence limitations should be sufficiently transparent.
Complete scope
Every indication, population, variant, configuration, accessory, and material claim is represented in the evidence analysis.
Balanced evidence
Favorable and unfavorable findings, conflicting studies, evidence limitations, and residual uncertainty are addressed.
Clinically meaningful conclusions
Statistical findings are interpreted in clinical context and conclusions do not exceed what the evidence supports.
Actionable gaps
Each remaining uncertainty is connected to a proportionate PMS or PMCF activity, endpoint, timeline, and potential action.
A CER is defensible when the reader can understand not only what the manufacturer concluded, but how the evidence supports that conclusion.
Primary regulatory references